An Intro to Emblaveo (aztreonam + avibactam)

The FDA web site usually provides label and review documents for approved drugs.[1]  Emblaveo, the combination of aztreonam and avibactam, was approved in February 2025, almost ½ year ago, but clinical review documents are still not posted at the site.[2]  Hence, we do not know how Regulators felt about the Continue reading An Intro to Emblaveo (aztreonam + avibactam)

NEW IDSA cUTI GUIDELINE

A new Guideline for the treatment of cUTI just arrived.[1] First, we are glad that this somewhat mundane topic receives the attention it deserves.  UTIs are often downplayed as minor infections, but the cUTI variety should not be taken lightly.  Many patients still are admitted with life-threatening infections, so prompt Continue reading NEW IDSA cUTI GUIDELINE

JOURNAL BUSINESS vs EDITORIAL OVERSIGHT

New medical and science journals pop up in our mailbox on a biweekly basis.  Offers to join as Editor, solicitation for articles based on past publications, invitations for subject reviews come as unsolicited emails.  Medical publication houses, old and new, are expanding, adding more and more subspecialties to their established Continue reading JOURNAL BUSINESS vs EDITORIAL OVERSIGHT